Cargando…

Mini‐review: Glucagon responses in type 1 diabetes – a matter of complexity

In recent years the role of altered alpha cell function and glucagon secretion in type 1 diabetes has attracted scientific attention. It is well established that glucagon responses to hypoglycemia are absent in type 1 diabetes, but more uncertain whether it is intact following other physiological an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bisgaard Bengtsen, Mads, Møller, Niels
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8371343/ https://www.ncbi.nlm.nih.gov/pubmed/34405569 http://dx.doi.org/10.14814/phy2.15009

Ejemplares similares

Hospitalization for hypoglycaemia in people with diabetes in Denmark, 1997–2017: Time trends in incidence and HbA(1c) and glucose‐lowering drug use before and after hypoglycaemia
por: Bengtsen, Mads Bisgaard, et al.
Publicado: (2021)

Experimentally Induced Hypoglycemia-associated Autonomic Failure in Humans: Determinants, Designs, and Drawbacks
por: Bisgaard Bengtsen, Mads, et al.
Publicado: (2022)

A model mimicking catabolic inflammatory disease; a controlled randomized study in humans
por: Mose, Maike, et al.
Publicado: (2020)

Effect of Mini-Dose Ready-to-Use Liquid Glucagon on Preventing Exercise-Associated Hypoglycemia in Adults With Type 1 Diabetes
por: Aronson, Ronnie, et al.
Publicado: (2023)

Hyperpolarized [1‐(13)C]pyruvate combined with the hyperinsulinaemic euglycaemic and hypoglycaemic clamp technique in skeletal muscle in a large animal model
por: Bengtsen, Mads Bisgaard, et al.
Publicado: (2021)

Why Glucagon Matters for Hypoglycemia and Physical Activity in Individuals With Type 1 Diabetes
por: Colberg, Sheri R.
Publicado: (2022)

Early Loss of the Glucagon Response to Hypoglycemia in Adolescents With Type 1 Diabetes
por: Siafarikas, Aris, et al.
Publicado: (2012)

Response to “Preserved” glucagon secretion in fulminant type 1 diabetes
por: Takahashi, Nobuyuki, et al.
Publicado: (2018)

Use of Glucagon in Patients With Type 1 Diabetes
por: Haymond, Morey W., et al.
Publicado: (2019)

Glucagon Nasal Powder: A Promising Alternative to Intramuscular Glucagon in Youth With Type 1 Diabetes
por: Sherr, Jennifer L., et al.
Publicado: (2016)

“Preserved” glucagon secretion in fulminant type 1 diabetes
por: Murase‐Mishiba, Yuko, et al.
Publicado: (2018)

Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans
por: Modrzynska, Justyna, et al.
Publicado: (2021)

Home Use of Mini-Dose Glucagon As a Novel Treatment for Hypoglycemia Following Repeated, Prolonged Fasts in Type 1 Diabetes During Ramadan
por: Algeffari, Metab, et al.
Publicado: (2022)

The Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review
por: Guo, Keyu, et al.
Publicado: (2021)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Positive Predictive Values of Procedure Codes on the Treatment of Non-Muscle Invasive Bladder Cancer in the Danish National Patient Registry
por: Blichert-Refsgaard, Linea, et al.
Publicado: (2022)

Soluble CD163 correlates with lipid metabolic adaptations in type 1 diabetes patients during ketoacidosis
por: Svart, Mads, et al.
Publicado: (2018)

Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes
por: Matsumoto, Shinobu, et al.
Publicado: (2013)

Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes
por: Kjeldsen, Sasha A S, et al.
Publicado: (2023)

Glucagon secretions are impaired in patients with fulminant type 1 diabetes
por: Komada, Hisako, et al.
Publicado: (2019)

Acute urinary retention in men: 21‐year trends in incidence, subsequent benign prostatic hyperplasia‐related treatment and mortality: A Danish population‐based cohort study
por: Bengtsen, Maria Bisgaard, et al.
Publicado: (2022)

The once‐daily human glucagon‐like peptide‐1 analog, liraglutide, improves β‐cell function in Japanese patients with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2012)

Lack of Association Between Residual Insulin Production and Glucagon Response to Hypoglycemia in Youth With Short Duration of Type 1 Diabetes
por: Sherr, Jennifer, et al.
Publicado: (2013)

β-Lactoglobulin Elevates Insulin and Glucagon Concentrations Compared with Whey Protein—A Randomized Double-Blinded Crossover Trial in Patients with Type Two Diabetes Mellitus
por: Smedegaard, Stine B., et al.
Publicado: (2021)

Association of Basal Hyperglucagonemia with Impaired Glucagon Counterregulation in Type 1 Diabetes
por: Farhy, Leon S., et al.
Publicado: (2012)

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
por: Hinnen, Deborah
Publicado: (2017)

Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?
por: Larsen, Matthias Ploug, et al.
Publicado: (2017)

Glucagon‐like peptide‐1 therapy for youth with type 2 diabetes
por: Cho, Young Min
Publicado: (2022)

Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon‐like peptide‐1/glucagon receptor agonist SAR425899 in comparison with liraglutide
por: Schiavon, Michele, et al.
Publicado: (2021)

Transdermal Estrogen Therapy Improves Gains in Skeletal Muscle Mass After 12 Weeks of Resistance Training in Early Postmenopausal Women
por: Dam, Tine Vrist, et al.
Publicado: (2021)

Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011)

Glucagon-like peptide 1 improved glycemic control in type 1 diabetes
por: Behme, Margaret T, et al.
Publicado: (2003)

Radiation Matters of the Heart: A Mini Review
por: Menezes, Kareena M., et al.
Publicado: (2018)

The role of glucagon on type 2 diabetes at a glance
por: Godoy-Matos, Amélio F
Publicado: (2014)

Glucagon and heart in type 2 diabetes: new perspectives
por: Ceriello, Antonio, et al.
Publicado: (2016)

Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
por: Eriksson, Olof, et al.
Publicado: (2020)

Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes
por: Castle, Jessica R., et al.
Publicado: (2010)

Response to “Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment”
por: Brooks, Anne B., et al.
Publicado: (2020)

What Is the Mechanism Driving the Reduction of Cardiovascular Events from Glucagon-like Peptide-1 Receptor Agonists?—A Mini Review
por: Berndt, Jared, et al.
Publicado: (2021)

Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved β-Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes
por: Jørgensen, Nils B., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_v53k2qgb4l6cqmpcfv2bddj1eu